• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Expert Rev Vaccines . Designing an Efficient Multi-Epitope Vaccine Displaying Interactions with Diverse HLA Molecules for an Efficient Humoral and

tetano

Editor, Senior Moderator
Expert Rev Vaccines


. 2020 Sep 1.
doi: 10.1080/14760584.2020.1811091. Online ahead of print.
Designing an Efficient Multi-Epitope Vaccine Displaying Interactions with Diverse HLA Molecules for an Efficient Humoral and Cellular Immune Response to prevent COVID-19 infection


Mrutyunjay Suar[SUP] 1 [/SUP], Soumya Mahapatra[SUP] 1 [/SUP], Susrita Sahoo[SUP] 1 [/SUP], Budheswar Dehury[SUP] 1 [/SUP], Vishakha Raina[SUP] 1 [/SUP], Shubhransu Patro[SUP] 1 [/SUP], Namrata Misra[SUP] 1 [/SUP]



Affiliations

Abstract

Background: The novel SARS-CoV-2 coronavirus, the causative agent of the ongoing pandemic COVID-19 disease continues to infect people globally and has infected millions of humans worldwide. However, no effective vaccine against this virus exists.
Method: Using Immunoinformatics, epitopic sequences from multiple glycoproteins that play crucial role in pathogenesis were identified. Particularly, epitopes were mapped from conserved receptor-binding domain of spike protein which have been experimentally validated in SARS-CoV-1 as a promising target for vaccine development.
Results: A multi-epitopic vaccine construct comprising of B-cell, CTL, HTL epitopes was developed alongwith fusion of adjuvant and linkers. The epitopes identified herein are reported for the first time and were predicted to be highly antigenic, stable, non-allergen, nontoxic and displayed conservation across several SARS-CoV-2 isolates from different countries. Additionally, the epitopes associated with maximum HLA alleles and population coverage analysis shows the proposed epitopes would be a relevant representative of large proportion of the world population. A reliable three-dimensional structure of the vaccine construct was developed. Consequently, docking and molecular-dynamics simulation ensured the stable interaction between vaccine and innate-immune receptor.
Conclusion: The promiscuous epitopes capable of inducing humoral and cellular immune response can be considered as potential vaccine candidates against SARS-CoV-2.

Keywords: COVID-19; Immunoinformatics; SARS-CoV-2; multi-epitopic vaccine; receptor-binding domain.
 
Back
Top